IDO (Protein|Antibody|cDNA Clone|ELISA Kit)

All IDO reagents are produced in house and quality controlled, including 3 IDO Antibody, 43 IDO Gene, 2 IDO Protein, 1 IDO qPCR. All IDO reagents are ready to use.

Recombinant IDO proteins are expressed by E. coli with fusion tags as N-His, N-cleavage.

IDO antibodies are validated with different applications, which are ELISA, IHC-P, WB, ICC/IF, IF.

IDO cDNA clones are full length sequence confirmed and expression validated. There are 13 kinds of tags for each IDO of different species, especially GFP tag, OFP tag, FLAG tag and so on. There are three kinds of vectors for choice, cloning vector, expression vector and lentivrial expression vector.

IDO Protein (2)


IDO Protein, Human, Recombinant (His Tag)


Expression host: E. coli

Human IDO1/Indoleamine 2,3‑dioxygenase Protein 9675

IDO Protein, Human, Recombinant


Expression host: E. coli

Human IDO1/Indoleamine 2,3‑dioxygenase Protein 9676

IDO Antibody (3)

Application Clonality

Anti-IDO Antibody


Specificity: Human

Application: ELISA,IHC-P

Clonality: PAb

Human IDO1/Indoleamine 2,3‑dioxygenase Immunohistochemistry(IHC) 18043

Anti-IDO Antibody


Specificity: Human

Application: ELISA

Clonality: PAb

Anti-IDO Antibody


Specificity: Human

Application: WB,ELISA,ICC/IF,IF

Clonality: PAb

Human IDO1/Indoleamine 2,3‑dioxygenase Immunofluorescence(IF) 14707

IDO cDNA Clone (43)


IDO qPCR Primer (1)

Indoleamine 2,3-dioxygenase-1, also known as Indoleamine-pyrrole 2,3-dioxygenase, IDO1 and IDO, is a member of the indoleamine 2,3-dioxygenase family. IDO1 / IDO and tryptophan 2,3-dioxygenase (TDO) are tryptophan-degrading enzymes that catalyze the first step in tryptophan catabolism via the kynurenine pathway. TDO is widely distributed in both eukaryotes and bacteria. In contrast, IDO has been found only in mammals and yeast. In 27, a third enzyme, indoleamine 2,3-dioxygenase-2 (IDO2), was discovered. IDO2 is found not only in mammals but also in lower vertebrates. IDO1 / IDO is an immunosuppressive molecule inducible in various cells. IDO1 / IDO catalyzes the cleavage of the pyrrol ring of tryptophan and incorporates both atoms of a molecule of oxygen. It mediates oxidative cleavage of tryptophan, an amino acid essential for cell proliferation and survival. IDO1 / IDO inhibition is proposed to have therapeutic potential in immunodeficiency-associated abnormalities, including cancer. The IDO pathway is activated in multiple tumor types. Selective inhibition of IDO1 may represent an attractive cancer therapeutic strategy via up-regulation of cellular immunity. IDO1 / IDO is an enzyme that suppresses adaptive T-cell immunity by catabolizing tryptophan from the cellular microenvironment. Inhibition of IDO pathway might enhance the efficacy of immunotherapeutic strategies for cancer.Immune Checkpoint
Immune Checkpoint Detection: ELISA Antibodies
Co-inhibitory Immune Checkpoint Targets Immunotherapy   Cancer Immunotherapy   Targeted Therapy